Farallon Capital Management

Renew Exim DMCC is owned by Valiant Investment DMCC.

Pentera is a leading provider of automated security validation solutions, designed to help organizations assess the integrity of their cybersecurity measures across their entire attack surface. The company's platform continuously evaluates potential security vulnerabilities by examining the threat levels within an organization's infrastructure, network, and human factors. This proactive approach allows businesses to perform ongoing cybersecurity tests, enabling them to identify and address security gaps in real-time. Trusted by thousands of security professionals and service providers globally, Pentera empowers organizations to enhance their security posture and mitigate risks before they can be exploited.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Canfor is one of the largest producers of sustainable lumber, pulp, and paper globally. Established in 1938 by John Prentice and L.L.G. Bentley in Vancouver, the company began as a small veneer plant and has since evolved into a respected leader in the forest products industry, employing over 5,000 people. Canfor operates primarily in North America and Europe, with lumber mills located in British Columbia, Alberta, the Southeastern United States, and Sweden. The company has two main segments: lumber, which encompasses sawmilling and remanufacturing operations, and pulp and paper, which includes kraft pulp, kraft paper, and bleached chemi-thermomechanical pulp. Canfor is recognized for its commitment to quality products, reliable supply, and exceptional customer service, while also focusing on sustainable, renewable resources to meet the growing global demand.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutic antibodies for inflammation and immuno-oncology. The company’s key product candidates include Etokimab, an anti-IL-33 treatment for atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis; and several immune cell modulating antibodies, including checkpoint agonists for autoimmune diseases. AnaptysBio's pipeline features notable immuno-oncology candidates such as TSR-042 (anti-PD-1), TSR-022 (anti-TIM-3), and TSR-075 (anti-PD-1/LAG-3 bispecific). The company employs a proprietary platform based on somatic hypermutation for antibody discovery and optimization, addressing unmet medical needs in therapeutic applications. AnaptysBio has formed partnerships with various organizations, including TESARO and Celgene, to enhance its research and development efforts. Founded in 2005, AnaptysBio has established itself in the biotechnology sector as a developer of innovative therapies targeting significant health challenges.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Atlas Capital Group, LLC is a real estate investment, development, and management firm founded in 2006 by Jeffrey A. Goldberger and Andrew B. Cohen. The company focuses on opportunistic and value-added real estate projects primarily in key gateway cities, notably New York and Los Angeles. Atlas Capital boasts a vertically integrated team of over 100 specialists who possess expertise across various real estate disciplines, including construction, leasing, development, asset management, property management, accounting, and legal services. This comprehensive approach enables Atlas Capital to effectively navigate the complexities of the real estate market and deliver value to its stakeholders.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

HiBob Inc. is a developer of a cloud-based human resources management system designed to modernize HR technology for contemporary workplaces. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in New York and London, HiBob offers its flagship product, Bob, which serves as an integrated human resource information system. This platform facilitates various HR functions, including attendance tracking, time-off management, employee records, compensation management, and performance evaluation. With an intuitive, data-driven design, Bob is tailored for the needs of globally distributed and collaborative work environments. Since its launch, HiBob has experienced significant growth and has become the preferred HRIS for over 1,000 midsize and multinational companies, helping them enhance employee engagement and retention through effective talent management.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Auna is a healthcare provider operating in Mexico, Peru, and Colombia. It manages a network of hospitals, clinics, and wellness facilities, offering prepaid healthcare plans, dental, and vision services. The company's revenue is primarily generated from its operations in Peru.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

GreenYellow is a company focused on generating electricity through centralized power plants and developing decentralized photovoltaic projects. It offers solar panels and energy supply services tailored for various sectors, including food retail, non-food retail, government agencies, and public utilities. By enabling clients to produce and manage their own energy, GreenYellow enhances value through solar photovoltaics, energy efficiency, and optimization. The company also operates energy efficiency contracts and provides monitoring services, helping clients reduce their energy costs and access cleaner energy alternatives compared to traditional sources.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Ada Health is a global health company based in Berlin, Germany, founded in 2011 by a team of doctors, scientists, and industry experts. The company has developed a virtual health companion platform that empowers users to actively manage their health and assists medical professionals in delivering effective care. Ada's platform utilizes personalized health inquiries to assess symptoms and offers features such as online video consultations, disease monitoring, and prevention strategies. The company collaborates with leading health systems and global non-profit organizations to enhance healthcare delivery and improve health outcomes for individuals.

Better Therapeutics is a company focused on the discovery, development, and commercialization of prescription digital therapeutics aimed at treating cardiovascular and metabolic diseases. It utilizes clinically validated, FDA-regulated software to promote behavior changes that address the underlying causes of these conditions, thereby enhancing quality of life, reducing reliance on medications, and lowering healthcare costs. The company's offerings include digital behavioral therapy that combines neuroscience, lifestyle medicine, and explainable artificial intelligence through a physician-prescribed mobile medical app. This approach leverages patient-generated data to guide clinical decision-making and optimize treatment outcomes. Better Therapeutics' current product pipeline features therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

HiBob Inc. is a developer of a cloud-based human resources management system designed to modernize HR technology for contemporary workplaces. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in New York and London, HiBob offers its flagship product, Bob, which serves as an integrated human resource information system. This platform facilitates various HR functions, including attendance tracking, time-off management, employee records, compensation management, and performance evaluation. With an intuitive, data-driven design, Bob is tailored for the needs of globally distributed and collaborative work environments. Since its launch, HiBob has experienced significant growth and has become the preferred HRIS for over 1,000 midsize and multinational companies, helping them enhance employee engagement and retention through effective talent management.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Zepz is an online money transfer service that enables individuals to send money to friends and family living abroad through computers, smartphones, or tablets. It provides a convenient and cost-effective alternative to traditional money transfer companies, which often charge high fees. Zepz allows users to send funds to over 140 destinations worldwide, including Europe, Asia, Africa, Australia, and the Americas. Recipients can receive money as bank deposits, cash pickups, Mobile Money, or mobile airtime top-ups. The platform is designed to facilitate secure international transfers, utilizing technology that allows customers to manage their funds efficiently, with lower processing fees compared to conventional methods. Zepz operates in 50 countries, aiming to simplify the process of remittance for its users.

Zentera Therapeutics is a biopharmaceutical company.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company leverages a portfolio of advanced radiopharmaceutical assets, expertise in radioisotopes like Actinium-225 and Lutetium-177, and innovative manufacturing technology. Point Biopharma Global's pipeline includes several promising candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, aiming to revolutionize theragnostic drug development and radioligand commercialization.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, focused on developing innovative therapies that restore protein homeostasis through targeted protein degradation. The company specializes in Protein Homeostatic Modulators and small molecule targeted protein degraders (TPDs), which utilize a unique mechanism involving molecular glues to regulate protein levels within the body. Their proprietary PRODEGY platform is built on a library of Cereblon binders, enabling the design of bifunctional and hybrid degraders aimed at treating various diseases, particularly cancer. BioTheryX's lead candidate, BTX-A51, is an oral small molecule and multi-kinase inhibitor targeting specific leukemic stem cells and oncogenic transcription factors. Established in 2007, BioTheryX aims to address significant unmet medical needs by leveraging its expertise in protein modulation and degradation.

NeoGenomics Laboratories operates a network of cancer-focused testing facilities in the United States, Switzerland, and Singapore. The company is divided into two main segments: Clinical Services and Pharma Services. It provides a range of genetic and molecular testing services, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing, aimed at helping clinicians and researchers understand cancer at a genetic level. Additionally, NeoGenomics offers morphologic analysis for diagnosis and supports pharmaceutical companies in their oncology programs through testing services that facilitate drug development and clinical trials. The company's collaboration with Inivata Limited for the commercialization of the InVisionFirst-Lung liquid biopsy test exemplifies its commitment to advancing cancer diagnostics. Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics serves hospitals, pathologists, oncologists, academic centers, and other clinical laboratories, enhancing cancer care through innovative testing solutions.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

LUMICKS specializes in advanced technologies for studying biology and cancer at the single-molecule and single-cell levels. The company focuses on bridging the gap between molecular structure and function, providing tools that enable real-time analysis of complex biological processes. Its flagship product, the C-Trap Optical Tweezers, combined with Fluorescence Microscopy, allows scientists to observe interactions at the single-molecule level. Additionally, the z-Movi Cell Avidity Analyzer measures and selects immune cells based on their real-time interactions with target cells. By facilitating live measurement and imaging, LUMICKS' instruments provide critical insights into the fundamental causes of diseases, including cancer, and hold potential for optimizing drug development.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients by discovering, developing, and commercializing innovative targeted therapies. The company's primary focus is on addressing drug resistance mutations in key driver oncogenes, which are mutated genes that contribute to the progression of cancer. By leveraging advanced technologies, Theseus Pharmaceuticals aims to create transformative treatments that can overcome challenges associated with existing therapies, thereby improving patient outcomes in oncology.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing innovative medicines for various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. Founded in 1997, the company focuses on pharmacology and pharmacokinetics, advancing several investigational drugs through clinical trials. Notable candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn’s disease, and Olorinab, currently in Phase IIb trials for abdominal pain linked to irritable bowel syndrome. Additionally, Arena is developing ralinepag for pulmonary arterial hypertension and APD418 for acute heart failure. The company has formed collaborations with several organizations, including United Therapeutics and Eisai, to enhance its research and expand its market presence. Arena Pharmaceuticals also has a marketed product, lorcaserin, approved for weight management, further demonstrating its commitment to addressing critical health challenges through innovative therapies.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Kesoram Industries Limited is a diversified manufacturing company based in Kolkata, India, established in 1919. Originally founded as Kesoram Cotton Mills Ltd., the company transitioned into producing rayon in 1959 and subsequently expanded into cement and tire manufacturing. Kesoram Industries markets its cement products under the Birla Shakti brand and offers a range of rayon, transparent paper, and filament yarn products under the Kesoram Rayon brand. The cement segment constitutes a significant portion of its revenue, primarily generated within the Indian market. In 1986, the company adopted its current name to better reflect its broadening portfolio and operations, which have continued to evolve over the decades.

AUTO1 Group, established in 2012 and headquartered in Berlin, Germany, operates a technology-driven used car marketplace. It connects buyers and sellers, including consumers and dealers, across Europe and North America. AUTO1 Group sources used cars from various channels such as original equipment manufacturers (OEMs), dealerships, and its own business units, then sells them through its global dealership network. The company's platform offers a simple, transparent, and convenient way to buy and sell used cars, with a focus on providing access to a wide range of certified vehicles.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Atento is the largest provider of customer relationship management (CRM) and business process outsourcing (BPO) services in Latin America. The company offers a comprehensive range of services, including customer care, sales, collections, back office, and technical support, catering to various sectors such as telecommunications, banking, financial services, healthcare, retail, and public administration. Atento serves its clients through multiple channels, including digital platforms like SMS, email, chat, social media, and applications, as well as traditional voice and in-person interactions. The company operates across several geographical regions, including Brazil, the Americas, and EMEA (Europe, the Middle East, and Africa).

CargoX is a technology-driven freight marketplace based in Sao Paulo, Brazil, established in 2013. The platform connects shipping companies with a network of over 1.4 million trucks, effectively addressing the issue of excess capacity in the transportation sector. By providing real-time information on available truck capacity, CargoX enhances freight visibility and helps shippers identify optimal solutions for transporting a wide range of products throughout Brazil. This approach not only reduces shipping costs for clients but also increases earnings for truck drivers while minimizing CO2 emissions associated with empty trucks on the road.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

ADVANCE.AI is a financial technology company focused on transforming the credit system through innovative data-driven solutions. With multiple offices across the Asia-Pacific region, it aims to create a more comprehensive and equitable alternative to traditional credit scoring methods. The company offers a big-data platform that includes anti-fraud detection services, assisting enterprises with loan applications through features such as multi-platform detection, face recognition, identity verification, company checks, and credit score analytics. By streamlining these processes, ADVANCE.AI helps businesses reduce manual verification costs and enhance operational efficiency. Founded by a team of experienced entrepreneurs and investors with backgrounds in prestigious institutions and industries, ADVANCE.AI is committed to building a better financial ecosystem.

Full Truck Alliance is a Chinese company that operates a platform connecting shippers with truckers to facilitate the transportation of goods over various distances and cargo weights. The company provides comprehensive services to both shippers and truckers through its mobile and web platforms. Its primary source of revenue comes from the use of these platforms for freight matching services, as well as additional value-added services. By streamlining the logistics process, Full Truck Alliance aims to enhance efficiency in freight transportation within the region.

Meituan Bike, previously known as Mobike, is a Chinese bicycle-sharing service that operates a fully station-less model. Founded in January 2015 by Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping, the company is headquartered in Beijing. Meituan Bike allows users to easily locate and rent bicycles through a mobile application, facilitating convenient transportation for short urban trips. The bicycles are equipped with smart locks and can be reserved via the app, offering a seamless user experience. In April 2018, the company was acquired by Meituan-Dianping for $2.7 billion and was rebranded as Meituan Bike in January 2019 as part of the integration process. The service has grown significantly since its inception, contributing to the development of urban mobility solutions in China.

Sea is a consumer internet company focused on enhancing the lives of consumers and small businesses in Southeast Asia through technology. Its primary businesses include Shopee, Garena, and SeaMoney. Shopee, the largest e-commerce platform in the region by gross merchandise value and transaction volume, operates as a hybrid C2C and B2C marketplace across eight key markets, with Indonesia being the largest contributor. Originally founded as a gaming company, Garena has evolved significantly, with its game Free Fire becoming the most downloaded game in early 2022 and a major revenue driver. SeaMoney complements these ventures by offering financial services, including lending, which is expected to grow in significance within the company’s portfolio. Through these diverse business lines, Sea aims to capitalize on the burgeoning digital economy in Southeast Asia.

The renewable energy arm of Hindustan Power Projects Pvt. Ltd .

PT Aplikasi Karya Anak Bangsa, commonly known as Gojek, is a mobile application-based platform founded in 2010 and headquartered in Jakarta, Indonesia. The company initially operated a motorcycle taxi fleet but has since evolved into a comprehensive Super App, offering a wide range of services including food delivery, transportation, digital payments, shopping, and various on-demand services such as massages. Launched in 2015, Gojek has rapidly become the largest consumer transactional technology group in Southeast Asia, driven by its commitment to speed, innovation, and social impact. The platform aims to empower the informal sector in the region while catering to diverse markets, including logistics, food, and entertainment.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Sohu.com Ltd is a prominent Chinese online media and technology company that offers a diverse range of products and services across various platforms. Established in 1995, Sohu operates several key websites, including its main portal Sohu.com, the interactive search engine Sogou.com, and the gaming information site 17173.com. It is also involved in the real estate sector through focus.cn and provides online gaming through its subsidiary Changyou.com, which features popular titles like Tian Long Ba Bu, DDTank, and Wartune. In addition to its online gaming ventures, Sohu delivers news and information services via mobile applications such as the Sohu News app and WAP.Sohu.com. The company generates revenue primarily through online brand advertising and is dedicated to serving millions of users with its community-based, web 2.0 products on both PCs and mobile devices.

AdsIt is an online video advertisement provider based in Beijing, China.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Beijing Adsit Media Technology Co., Ltd. is a Chinese company specializing in the distribution of internet-based video advertisements. It serves as both the operating entity and technology service provider for Baidu's TV business model, distinguishing itself as Baidu's sole strategic brand management partner. Adsit Media offers a range of innovative online video advertising services, including floating, embedded, and streaming video advertisements. These services are designed to help businesses attract customers and increase their revenue, making Adsit Media a key player in the advertising sector in China.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

E-House is a real estate services company in China offering a comprehensive online-to-offline (O2O) service platform. It offers primary sales agency services, online real estate services, real estate information and consulting services, real estate advertising services, real estate promotional event services, secondary real estate brokerage services, and real estate investment fund management services. E-House has served more than 80% of domestic real estate developers, including Vanke, Evergrande, Wanda, Longfor, Poly Real Estate, and many other real estate industry giants, and worked on more than 200,000 real estate projects. E-House was founded in 2004 and was first listed on the New York Stock Exchange in August 2007.

Heidi Coast Advertising Co., Ltd. is a Chinese company focused on the development and operation of campus media integrated marketing solutions. Heidi Coast Advertising’s leading brand, “China Campus Media,” covers new media such as campus video, campus outdoor, campus activity, CC176.com, and more. By cooperating with educational institutions and major domestic media organizations, the company spreads news, entertainment, programs, and advertisement information in universities and colleges, with students as the main audience group. It covers 18 economically developed cities and over 330 colleges and universities in China. It influences over 5 million people daily and maintains a campus broadcasting network.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.